Can-Vac

Identification of new goals for the prophylaxis and treatment of systemic candidiasis.

 

The "CanVac" research project is a research alliance against fungal infections supported by the EU. The aim of the project is to develop a prophylactic vaccine and treatment for the sometimes lethal infection which is triggered by the human-pathogenic Candida albicans fungus. The research focus is on the genomic approach.
The aim is to use the knowledge of the complete genomic sequence, and the diversity of selected
Candida strains, to advance the research on the virulence of Candida, and also the development of
vaccines and antibody-based treatments for infections by pathogenic Candida

 

GATC Biotech’s task:

Genome sequencing of selected Candida albicans strains using the latest sequencing technologies (Next Generation sequencing)

 

Participating partners:

The project is carried out as part of the EuroTransBio Consortium.

Copyright © 2014 GATC Biotech AG. All rights reserved.
RSS-Feed twitter facebook google plus linkedin xing